BioMarin Pharmaceutical 향후 성장

Future 기준 점검 2/6

BioMarin Pharmaceutical (는) 각각 연간 18.9% 및 5.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 19.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 12.8% 로 예상됩니다.

핵심 정보

18.9%

이익 성장률

19.17%

EPS 성장률

Biotechs 이익 성장	23.1%
매출 성장률	5.8%
향후 자기자본이익률	12.83%
애널리스트 커버리지	Good
마지막 업데이트	23 Dec 2025

최근 향후 성장 업데이트

Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts

Oct 30

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 06

Recent updates

BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight

Dec 26

Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts

Oct 30

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 06

Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Jul 22

Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment?

Apr 27

The Price Is Right For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Mar 31

The Strong Earnings Posted By BioMarin Pharmaceutical (NASDAQ:BMRN) Are A Good Indication Of The Strength Of The Business

Mar 04

BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Feb 21

BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy

Jan 23

이익 및 매출 성장 예측

NasdaqGS:BMRN - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	3,855	1,197	1,247	1,504	9
12/31/2027	3,607	943	1,177	1,375	13
12/31/2026	3,392	831	1,038	1,250	18
12/31/2025	3,171	546	635	598	24
9/30/2025	3,094	520	826	914	N/A
6/30/2025	3,064	657	691	767	N/A
3/31/2025	2,950	524	620	700	N/A
12/31/2024	2,854	427	485	573	N/A
9/30/2024	2,753	322	311	415	N/A
6/30/2024	2,588	257	223	329	N/A
3/31/2024	2,472	205	173	280	N/A
12/31/2023	2,419	168	52	159	N/A
9/30/2023	2,311	147	25	139	N/A
6/30/2023	2,235	100	34	161	N/A
3/31/2023	2,173	72	15	147	N/A
12/31/2022	2,096	142	148	176	N/A
9/30/2022	2,008	84	151	180	N/A
6/30/2022	1,912	54	106	119	N/A
3/31/2022	1,880	39	134	146	N/A
12/31/2021	1,846	-64	185	305	N/A
9/30/2021	1,849	16	165	280	N/A
6/30/2021	1,917	837	155	269	N/A
3/31/2021	1,844	795	92	214	N/A
12/31/2020	1,860	854	15	85	N/A
9/30/2020	1,863	852	75	156	N/A
6/30/2020	1,847	122	58	140	N/A
3/31/2020	1,805	114	3	88	N/A
12/31/2019	1,704	-24	-90	48	N/A
9/30/2019	1,603	-43	-59	40	N/A
6/30/2019	1,533	-110	N/A	17	N/A
3/31/2019	1,519	-90	N/A	8	N/A
12/31/2018	1,491	-77	N/A	20	N/A
9/30/2018	1,496	-125	N/A	-15	N/A
6/30/2018	1,439	-125	N/A	-23	N/A
3/31/2018	1,383	-145	N/A	29	N/A
12/31/2017	1,314	-117	N/A	-9	N/A
9/30/2017	1,255	-156	N/A	-24	N/A
6/30/2017	1,201	-181	N/A	-72	N/A
3/31/2017	1,184	-563	N/A	-137	N/A
12/31/2016	1,117	-630	N/A	-228	N/A
9/30/2016	1,045	-471	N/A	-293	N/A
6/30/2016	974	-524	N/A	-286	N/A
3/31/2016	924	-187	N/A	-253	N/A
12/31/2015	890	-172	N/A	-219	N/A
9/30/2015	892	-310	N/A	-179	N/A
6/30/2015	859	-212	N/A	-185	N/A
3/31/2015	801	-163	N/A	-183	N/A

애널리스트 향후 성장 전망

수입 대 저축률: BMRN 의 연간 예상 수익 증가율(18.9%)이 saving rate(3.3%)보다 높습니다.

수익 vs 시장: BMRN 의 연간 수익(18.9%)이 US 시장(15.9%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: BMRN 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: BMRN 의 수익(연간 5.8%)이 US 시장(연간 10.4%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: BMRN 의 수익(연간 5.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: BMRN의 자본 수익률은 3년 후 12.8%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/31 06:47
종가	2025/12/31 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

BioMarin Pharmaceutical Inc.는 51명의 분석가가 다루고 있습니다. 이 중 18명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Jack Allen	Baird
Ying Huang	Barclays
Huidong Wang	Barclays

BioMarin Pharmaceutical 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Consensus EPS estimates fall by 13%

Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts

BioMarin Pharmaceutical Inc. Revises Earnings Guidance for the Fiscal Year 2025

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

BioMarin Pharmaceutical Inc. Updates Earnings Guidance for the Full Year 2025

BioMarin Pharmaceutical Inc. Reaffirms Earnings Guidance for Full Year 2025

Recent updates

BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight

Investor sentiment improves as stock rises 17%

BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) agreed to acquire Amicus Therapeutics, Inc. (NasdaqGM:FOLD) for $4.7 billion.

Consensus EPS estimates fall by 13%

Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts

FDA Accepts BioMarin's PALYNZIQ® (Pegvaliase-Pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria

Third quarter 2025 earnings: EPS misses analyst expectations

BioMarin Pharmaceutical Inc. Revises Earnings Guidance for the Fiscal Year 2025

BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from FTSE All-World Index (USD)

Biomarin Pharmaceutical Inc. Shares New Data Reinforcing Its Leadership in Bone Health At the American Society for Bone and Mineral Research Annual Meeting

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

BioMarin Pharmaceutical Inc. Updates Earnings Guidance for the Full Year 2025

BioMarin Pharmaceutical Inc. Announces Appointment of Ian T. Clark to Board of Directors, Effective August 1, 2025

Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) completed the acquisition of Inozyme Pharma, Inc. (NasdaqGS:INZY).

BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell 1000 Defensive Index

Biomarin Pharmaceutical Inc. Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of Roctavian

BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) agreed to acquire Inozyme Pharma, Inc. (NasdaqGS:INZY) for approximately $260 million.

BioMarin Pharmaceutical Inc. Presents New Data for Vosoritide in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

First quarter 2025 earnings: EPS exceeds analyst expectations

BioMarin Pharmaceutical Inc. Reaffirms Earnings Guidance for Full Year 2025

Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment?

BioMarin Pharmaceutical Inc., Annual General Meeting, May 20, 2025

Investor sentiment deteriorates as stock falls 16%

BioMarin Pharmaceutical Inc. Announces Positive Pivotal Data for PalyNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria

The Price Is Right For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Biomarin Pharmaceutical Inc. Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with Vosoritide in Children Under 3 with Achondroplasia At 2025 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting

The Strong Earnings Posted By BioMarin Pharmaceutical (NASDAQ:BMRN) Are A Good Indication Of The Strength Of The Business

High number of new directors

BioMarin Pharmaceutical Inc. Announces Appointment of Timothy P. Walbert to Board of Directors

BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Full year 2024 earnings: EPS and revenues exceed analyst expectations

BioMarin Pharmaceutical Inc. Provides Earnings Guidance for Full Year 2025

BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy

Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biomarin Pharmaceutical Inc. Revises Earnings Guidance for the Full Year 2024

Price target decreased by 7.0% to US$104

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia At 2024 International Skeletal Dysplasia Society Meeting

Investor sentiment deteriorates as stock falls 17%

Biomarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2024 and for Fiscal Year 2027

BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024

BioMarin Pharmaceutical Inc. Announces Management Changes

Consensus EPS estimates increase by 10%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease

BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024

BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell Small Cap Comp Growth Index

Executive VP notifies of intention to sell stock

BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain

Director notifies of intention to sell stock

Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® (Vosoritide) in Children

First quarter 2024 earnings: EPS exceeds analyst expectations

Consensus EPS estimates increase by 17%

Director notifies of intention to sell stock

BioMarin Pharmaceutical Inc., Annual General Meeting, May 21, 2024

Executive VP notifies of intention to sell stock

Insider recently sold US$3.0m worth of stock

Insider notifies of intention to sell stock

Biomarin Announces Board Changes, Effective May 20, 2024

BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth

Full year 2023 earnings released: EPS: US$0.89 (vs US$0.76 in FY 2022)

BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Year 2024

Director notifies of intention to sell stock

BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?

Biomarin Pharmaceutical Inc. Announces Resignation of Jeffrey Ajer as Executive Vice President and Chief Commercial Officer, Effective from July 1, 2024

Director notifies of intention to sell stock